Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Bioengineering in Vaccine Design and Delivery
share announcement

Bioengineering in Vaccine Design and Delivery

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Attenuated/Inactivated/Live and Vectored Vaccines".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 2125

Special Issue Editor

Prof. Dr. Massimo Zollo

E-Mail Website
Guest Editor
Department of Molecular Medicine and Medical Biotechnology, Federico II Faculty of Naples, 80138 Napoli, Italy
Interests: cancer genetics; molecular oncology; pediatric brain cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

During vaccine development, it is essential to improve delivery and manufacturing methods to reach the safe, effective, and cost-effective vaccine production criteria.

Advances in bioengineering have made it possible to control the physicochemical properties of the vaccines for faster synthesis, improve the antigen presentation to get more robust immunogenicity of vaccines, and obtain safer vaccine formulas.

Recent developments in vaccine delivery include the development of various polymeric particles as vaccine carriers due to their high biocompatibility and biodegradability, such as PLGA, PEG, polycaprolactone, dextran, chitosan, and self-assembled peptides. It is also shown that biodegradable hyaluronic cryogel mediates sustained antigen and adjuvant release, leading to a durable immune response. Proof of concept studies in vitro and in vivo will also be considered. 

Virus-like particles have also been used and tested as vaccine carriers because of their size and shape, which resemble the actual size and shape of native viruses. VLPs also efficiently elicit the immune response and offer improved safety, especially for immunocompromised or elderly patients, as they lack viral genomes, so there is no potential for replication within the target cells.

Scientists working on different strategies to improve vaccine effectiveness, safety, or manufacturing using bioengineering technology are welcome to submit their work to this Special Issue by August 2024.

Prof. Dr. Massimo Zollo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine design
  • vaccine delivery
  • vaccine synthesis
  • vaccine carriers
  • virus-like particles

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

21 pages, 1865 KiB  
Article
Intranasally Delivered Adenoviral Vector Protects Chickens against Newcastle Disease Virus: Vaccine Manufacturing and Stability Assessments for Liquid and Lyophilized Formulations
by Omar Farnós, Barbara Cristina Martins Fernandes Paes, Belayneh Getachew, Samia Rourou, Ameni Chaabene, Esayas Gelaye, Takele A. Tefera and Amine A. Kamen
Vaccines 2024, 12(1), 41; https://doi.org/10.3390/vaccines12010041 - 29 Dec 2023
Viewed by 1319
Abstract
Newcastle disease (ND) remains a critical disease affecting poultry in sub-Saharan Africa. In some countries, repeated outbreaks have a major impact on local economies and food security. Recently, we developed an adenovirus-vectored vaccine encoding the Fusion protein from an Ethiopian isolate of Newcastle [...] Read more.
Newcastle disease (ND) remains a critical disease affecting poultry in sub-Saharan Africa. In some countries, repeated outbreaks have a major impact on local economies and food security. Recently, we developed an adenovirus-vectored vaccine encoding the Fusion protein from an Ethiopian isolate of Newcastle disease virus (NDV). The adenoviral vector was designed, and a manufacturing process was developed in the context of the Livestock Vaccine Innovation Fund initiative funded by the International Development Research Centre (IDRC) of Canada. The industrially relevant recombinant vaccine technology platform is being transferred to the National Veterinary Institute (Ethiopia) for veterinary applications. Here, a manufacturing process using HEK293SF suspension cells cultured in stirred-tank bioreactors for the vaccine production is proposed. Taking into consideration supply chain limitations, options for serum-free media selection were evaluated. A streamlined downstream process including a filtration, an ultrafiltration, and a concentration step was developed. With high volumetric yields (infectious titers up to 5 × 109 TCID50/mL) in the culture supernatant, the final formulations were prepared at 1010 TCID50/mL, either in liquid or lyophilized forms. The liquid formulation was suitable and safe for mucosal vaccination and was stable for 1 week at 37 °C. Both the liquid and lyophilized formulations were stable after 6 months of storage at 4 °C. We demonstrate that the instillation of the adenoviral vector through the nasal cavity can confer protection to chickens against a lethal challenge with NDV. Overall, a manufacturing process for the adenovirus-vectored vaccine was developed, and protective doses were determined using a convenient route of delivery. Formulation and storage conditions were established, and quality control protocols were implemented. Full article
(This article belongs to the Special Issue Bioengineering in Vaccine Design and Delivery)
►▼ Show Figures

Figure 1

Other

Jump to: Research

9 pages, 989 KiB  
Brief Report
Binding of Natural Antibodies Generated after COVID-19 and Vaccination with Individual Peptides Corresponding to the SARS-CoV-2 S-Protein
by Anna M. Timofeeva, Sergey E. Sedykh, Ekaterina A. Litvinova, Sergey A. Dolgushin, Andrey L. Matveev, Nina V. Tikunova and Georgy A. Nevinsky
Vaccines 2024, 12(4), 426; https://doi.org/10.3390/vaccines12040426 - 17 Apr 2024
Viewed by 510
Abstract
The rapid development of vaccines is a crucial objective in modern biotechnology and molecular pharmacology. In this context, conducting research to expedite the selection of a potent immunogen is imperative. The candidate vaccine should induce the production of antibodies that can recognize the [...] Read more.
The rapid development of vaccines is a crucial objective in modern biotechnology and molecular pharmacology. In this context, conducting research to expedite the selection of a potent immunogen is imperative. The candidate vaccine should induce the production of antibodies that can recognize the immunogenic epitopes of the target protein, resembling the ones found in recovered patients. One major challenge in vaccine development is the absence of straightforward and reliable techniques to determine the extent to which the spectrum of antibodies produced after vaccination corresponds to antibodies found after recovery. This paper describes a newly developed method to detect antibodies specific to immunogenic epitopes of the target protein in blood plasma and to compare them with antibody spectra generated post vaccination. Comparing the antibody pool generated in the human body after recovering from an infectious disease with the pool formed through vaccination can become a universal method for screening candidate vaccines. This method will enable the identification of candidate vaccines that can induce the production of antibodies similar to those generated in response to a natural infection. Implementing this approach will facilitate the rapid development of new vaccines, even when faced with a pandemic. Full article
(This article belongs to the Special Issue Bioengineering in Vaccine Design and Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop